Drug Trial Radar · NCT04223193
Flexible-Dose Trial in Early Parkinson's Disease (PD)
Last checked: Nov 19, 2026Latest source record: Nov 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
304
Actual
Start
Jan 6, 2020
Primary completion
Oct 1, 2024
Study completion Oct 1, 2024
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Jan 10, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the efficacy, safety, tolerability and pharmacokinetics (PK) of flexible doses of tavapadon in participants with Parkinson's Disease.
Conditions
- Parkinson Disease
Interventions
TavapadonDrug
Participants will be randomized to receive tavapadon 5 mg QD to 15 mg QD tablet once daily orally for 27 weeks.
PlaceboDrug
Participants will receive placebo matching to tavapadon QD orally for 27 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in the Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts II and III Combined ScoreTime frame: Week 26
Locations
53 sites in 13 countries. Site status is shown where the registry gives one.
Fresno, California
Fresno, California
Boca Raton, Florida
Boca Raton, Florida
Maitland, Florida
Maitland, Florida
Ocala, Florida
Ocala, Florida
Winter Park, Florida
Winter Park, Florida
Boston Neuro Research Center
North Dartmouth, Massachusetts
Albany, New York
Albany, New York
Syracuse, New York
Syracuse, New York
Cincinnati, Ohio
Cincinnati, Ohio
Cleveland, Ohio
Cleveland, Ohio
Memphis, Tennessee
Memphis, Tennessee
Cypress, Texas
Cypress, Texas
Houston, Texas
Houston, Texas
Lubbock, Texas
Lubbock, Texas
Round Rock, Texas
Round Rock, Texas
Richmond, Virginia
Richmond, Virginia
Richmond, Virginia
Richmond, Virginia
Kirkland, Washington
Kirkland, Washington
Macquarie Park, New South Wales
Sydney, New South Wales, Australia
Marseille, France
Marseille, France, France
Nantes CEDEX 1
Nantes, Nantes, France
Toulouse Cedex 9
Toulouse, Toulouse, France
Bochum
Bochum, Bochum, Germany
Gera
Gera, Gera, Germany
Muenchen
München, Muenchen, Germany
Berlin
Berlin, State of Berlin, Germany
Tatabanya
Tatabánya, Hungary
Budapest
Budapest, Budapest, Hungary
Pecs
Pécs, Hungary, Hungary
Rozzano Milano
Rozzano, Italy
Torino
Torino, Italy
Cassino
Cassino, Cassino, Italy
Milano
Milan, Milano, Italy
Rome
Rome, Rome, Italy
Centrum Medyczne NEUROMED
Bydgoszcz, Poland
Centrum Medyczne Hope Clinic Sebastian Szklener
Lublin, Poland
Cracow
Krakow, Cracow, Poland
Katowice
Katowice, Katowice, Poland
Siemianowice Slaskie
Siemianowice Śląskie, Siemianowice Slaskie, Poland
Belgrade
Belgrade, Belgrade, Serbia
Showing 40 of 53 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.